A multicenter, randomized, double-blind, placebo-controlled phase II trial of ansofaxine hydrochloride extended release tablets (LY03005) in the patients with major depressive disorder.

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled phase II trial of ansofaxine hydrochloride extended release tablets (LY03005) in the patients with major depressive disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2018

At a glance

  • Drugs LY 03005 (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Feb 2018 New trial record
    • 23 Jan 2018 According to a Luye Pharma Group media release, primary endpoint (Reduction in 17- item Hamilton Rating Scale) has been met.
    • 23 Jan 2018 Results presented in a Luye Pharma Group Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top